IP Library › Granted Patent US 10,712,339
Granted Patent B2
US 10,712,339 · App. 15/730,335 · Granted Jul 14, 2020

Engineering of a novel breast tumor microenvironment on a microfluidic chip

Inventors: Mehdi Nikkhah (Scottsdale, AZ); Danh Truong (Tempe, AZ)
Assignee: Arizona Board of Regents on behalf of Arizona State University
G01N33/5011B01L3/502707B01L3/502715C12M23/16C12M25/14B01L2300/0816B01L2300/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,712,339
App. No.
15/730,335
Granted
Jul 14, 2020
Kind
B2
Abstract

A microfluidic device for more accurately modeling the in vitro environment in which cancer occurs is disclosed. The microfluidic device includes a surface defining one or more microfluidic channels, a first three dimensional scaffold comprising one or more cancer cells that is spatially separated from the one or more microfluidic channels, a second three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the first three dimensional scaffold, and that is spatially separated from the one or more microfluidic channels, and a third three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the one or more microfluidic channels and the second three dimensional scaffold. The device can be used to assay anti-cancer agents, or as a system for modeling the growth, behavior, or metastasis and tumor formation of cancer cells.

Claims (31)

1. A microfluidic device, comprising:

a surface defining one or more microfluidic channels, wherein the surface extends beyond the one or more microfluidic channels;

a first three dimensional scaffold comprising one or more cancer cells that is spatially separated from the one or more microfluidic channels;

a second three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the first three dimensional scaffold, and that is spatially separated from the one or more microfluidic channels; and

a third three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the one or more microfluidic channels and the second three dimensional scaffold, wherein the extended surface underlies the first, second and third three dimensional scaffolds.

2. The microfluidic device of claim 1 , wherein the one or more cancer cells are metastatic or tumorigenic cancer cells.

3. The microfluidic device of claim 1 , wherein the one or more cancer cells are breast cancer cells.

4. The microfluidic device of any of claim 1 , wherein the second three dimensional scaffold comprises one or more stromal cells.

5. The microfluidic device of claim 4 , wherein the one or more stromal cells are fibroblasts.

6. The microfluidic device of claim 1 , wherein the second three dimensional scaffold comprises one or more macrophages.

7. The microfluidic device of claim 1 , wherein the third three dimensional scaffold comprises one or more endothelial cells.

8. The microfluidic device of claim 1 , wherein the one or more of the microfluidic channels comprises one or more growth factors.

9. The microfluidic device of claim 1 , wherein at least one of the first three dimensional scaffold, the second three dimensional scaffold, and the third three dimensional scaffold comprise a gel matrix.

10. The microfluidic device of claim 9 , wherein the gel matrix comprises one or more of the group consisting of collagen, fibronectin, fibrinogen, hyaluronan, a hydrogel, a peptide gel, a gel-like protein or interpenetrating network hydrogels.

11. The microfluidic device of claim 9 , wherein the gel matrix comprises a collagen hydrogel.

12. The microfluidic device of claim 8 , wherein the surface extends beyond the one or more microfluidic channels defined thereby, and wherein the extended surface underlies both the first, second, and third three dimensional scaffolds.

13. The microfluidic device of claim 12 , wherein the surface further comprises microposts separating at least one of the first three dimensional scaffold, the second three dimensional scaffold, the third three dimensional scaffold, and the one or more microfluidic channels along the portion that contacts.

14. The microfluidic device of claim 1 , further comprising one of more inlets for adding at least one of the first three dimensional scaffold, the second three dimensional scaffold, and the third three dimensional scaffold to the microfluidic device.

15. The microfluidic device of claim 1 , wherein one or more of the microfluidic channels comprises one or more fluidic inlets suitable for introducing a test agent into the microfluidic device.

16. The microfluidic device of claim 14 , wherein the one or more microfluidic channels comprises a first microfluidic channel on a first side of the third three dimensional scaffold and a second microfluidic channel on an opposite second side of the third three dimensional scaffold.

17. The microfluidic device of claim 1 , wherein the one or more cancer cells are obtained directly from a cancer patient in need of treatment.

18. The microfluidic device of claim 5 , wherein the fibroblasts are obtained directly from a cancer patient in need of treatment.

19. The microfluidic device of claim 6 , wherein the one or more macrophages are obtained directly from a cancer patient in need of treatment.

20. The microfluidic device of claim 7 , wherein the one or more endothelial cells are obtained directly from a cancer patient in need of treatment.

21. A method of assaying a test agent for anti-cancer activity, comprising:

introducing the test agent to the microfluidic device of claim 15 through the one or more fluidic inlets; and

observing the cancer cells within the microfluidic device to determine the effect of the test agent.

22. The method of claim 18 , wherein the cancer cells are obtained directly from a patient in need of treatment or commercially available cells lines.

23. A method of studying cancer or related cells, comprising:

observing one or more of the cancer cells or related cells within the microfluidic device of claim 1 .

24. The method of claim 20 , further comprising the steps of altering one or more microenvironments within the microfluidic device and determining the effect of the alteration on the one or more cancer cells or related cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2018
From: NIKKHAH, MEHDI; TRUONG, DANH
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 044516/0388 →
Continuity (3)
Continuation In Part 14872920 · Oct 1, 2015
Provisional Application 62058186 · Oct 1, 2014
Related Publication 20180052151A1 · Feb 22, 2018
Cited By (2)
US 12,427,517 US 12,533,673